"We are New England Retina Associates, our physicians specialize in the disease, injury, treatment and surgery of the retina and vitreous. Our practice has been providing Fairfield and New Haven Counties with excellent patient care for over 20 years. We have saved the eyesight of thousands of patients in CT, NY and in fact, the nation and the world. If you have questions, we urge you to contact us or call 203-288-2020."

During the past decade, New England Retina Associates conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 12 clinical trials were completed, i.e. on average, 109.1% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 5 clinical trials were completed. i.e. 500% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New England Retina Associates" #1 sponsor was "New England Retina Associates" with 3 trials, followed by "Allegro Ophthalmics, LLC" with 2 trials sponsored, "Apellis Pharmaceuticals, Inc." with 2 trials sponsored, "Eyetech Pharmaceuticals" with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New England Retina Associates" #1 collaborator was "Genentech, Inc." with 3 trials as a collaborator, "Duke University" with 2 trials as a collaborator, "Juvenile Diabetes Research Foundation" with 2 trials as a collaborator, "National Eye Institute (NEI)" with 2 trials as a collaborator and "Pfizer" with 2 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "New England Retina Associates" are "Geographic Atrophy" (4 trials), "Choroidal Melanoma" (3 trials), "Diabetic Macular Edema" (3 trials), "Diabetic Retinopathy" (2 trials) and "Macular Degeneration" (2 trials). Many other conditions were trialed in "New England Retina Associates" in a lesser frequency.

Most popular intervention types in "New England Retina Associates" are "Drug" (21 trials), "Other" (4 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Ranibizumab" (3 trials), "Sham Procedure" (3 trials), "Placebo" (2 trials), "pegaptanib sodium" (2 trials) and "0.5 mg Ranibizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "New England Retina Associates" are 23 trials for "All" genders.

Currently, there are NaN active trials in "New England Retina Associates". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in New England Retina Associates, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in New England Retina Associates, 2 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".